Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 years or older.
• People who have already had a leukapheresis procedure (a process where white blood cells are collected from the blood) and are scheduled to receive one of two specific CAR T-cell therapies (axicabtagene ciloleucel or lisocabtagene maraleucel) for a type of lymphoma called DLBCL, without being given corticosteroids beforehand to prevent certain side effects.
• People whose DLBCL has come back or stopped responding to treatment after at least one previous round of systemic therapy (treatment that travels through the whole body, such as chemotherapy).
• People who meet their hospital's standard requirements for receiving CAR T-cell therapy.
• People whose kidneys, liver, heart, and blood counts are functioning at an adequate level as measured by specific lab tests (confirm exact values with trial site).
• People whose lymphoma can be measured using standard imaging criteria.
• People with a general health and activity level rated as fully active or restricted only in physically strenuous activity (ECOG performance status 0 or 1 — confirm with trial site).
• People who are willing to use an approved form of birth control during the study and for 30 days afterward (applies to women who could become pregnant and all men).
• People who are willing and able to provide written consent, or who have a legal representative who can provide consent on their behalf.

Who may not be able to join:

• People who received cytotoxic chemotherapy (cell-killing cancer treatment) within 14 days before their leukapheresis procedure.
• People who have significant difficulty swallowing or absorbing medications that is not adequately managed with treatment (such as painful swallowing, trouble swallowing, or severe reflux).
• People with significantly abnormal levels of certain electrolytes (minerals in the blood such as potassium, sodium, calcium, or magnesium) that fall outside specified ranges (confirm exact values with trial site).
• People with a clinically significant abnormal heart rhythm reading on an ECG (heart tracing) at the start of the study, including a specific electrical measurement (QTcF) above a set threshold, or certain heart conduction or rhythm problems (confirm details with trial site).
• People with a known history of significant heart rhythm problems and/or who require blood-thinning or antiplatelet medications at therapeutic (treatment-level) doses.
• People with active significant heart or blood vessel disease, including a stroke within the last 6 months, a heart attack within the last 6 months, unstable chest pain, or moderate-to-severe heart failure.
• People who have had an uncontrolled blood clot event or a serious bleeding episode within the last 6 months.
• People with a known history of a bleeding disorder.
• People who need ongoing treatment-level doses of blood thinners, antiplatelet drugs, or clot-dissolving medications (a low preventative dose of a specific blood thinner called low molecular weight heparin is allowed).
• People whose resting systolic blood pressure (the top number in a blood pressure reading) is below 100 mmHg.
• People who have had an autoimmune disease or graft versus host disease requiring immune-suppressing treatment within the last 2 years (a very low dose of steroids equivalent to 5 mg or less of prednisone per day may be permitted — confirm with trial site).
• People who, in the judgment of the trial doctor, are unlikely to follow the study procedures or are considered unsuitable for other reasons.

Important: Always verify eligibility with the trial site directly before applying.